Skip to main content
FDA priority review status given to Clovis' ovarian cancer drug

Clovis Oncology's supplemental new drug application for Rubraca, or rucaparib, which is being developed as a maintenance treatment for female patients with recurrent, platinum-sensitive ovarian cancer with or without BRCA mutation, was granted priority review designation by the FDA. The agency's action date is April 6.

Full Story: